Algatech has Tripled its Production Capacity for FucoVital
01/10/2019
Following increased demand from the dietary supplements market, Algatech has tripled its fucoxanthin production capability. Algatech’s Fucovital proprietary fucoxanthin oleoresin is the world’s first microalgae derived extract standardised to 3% fucoxanthin, plus naturally occurring omega-3’s and other beneficial fatty acids.
Algatech has announced the appointment of Mr. Doron Safrai as its new Chief Executive Officer. Mr. Safrai’s appointment comes at an important moment in the company’s development as the company now looks forward to the launch of a new product related to the use of β-1,3-glucan derived from microalgae Euglena gracilis.
The growing demand for the fucoxanthin found in Algatech’s FucoVital has led to a tripling of Algatech’s fucoxanthin production capability. This is a significant step forward in meeting the growing demand for this powerful natural ingredient.
Algatech has licensed the rights and intellectual property related to the production of β-1,3-glucan from US biotech F3 Platform Biologics.
Algatech intends to launch several products using the algae-derived beta glucan, which will expand Algatech’s existing product offering and support its mission to develop commercial, microalgae-based products.
Algatech Ltd. has licensed the rights and intellectual property of technology belonging to F3 Platform Biologics that is designed to extract β-1,3-glucans from Euglena gracilis microalgae.